ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0060

Dietary Management of Rheumatoid Arthritis: A Functional Investigation of the Synbiotic Medical Food, SBD121
Abstract Number: 0133

Differences in cardiovascular risk factor control between primary and systemic lupus erythematosus-related antiphospholipid syndrome in a multiethnic cohort of 1003 patients with antiphospholipid syndrome: the SUrvey of cardiovascular disease Risk Factors (SURF) in SLE and APS project
Abstract Number: 2428

Differences in Dyspigmentation and Scarring Across Cutaneous Lupus Erythematosus Categories and Subtypes
Abstract Number: 2243

Differences In GDF-15 Levels In Rheumatoid Arthritis Patients With Remission Or Mild Disease Activity Are Associated With Fewer Depressive Symptoms: Clinical Data And Bioinformatic Analysis
Abstract Number: 1278

Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus
Abstract Number: 2574

Differences in SARS-CoV-2 Antigen Persistence in Individuals with Systemic Autoimmune Rheumatic Diseases Compared to the General Population
Abstract Number: 0367

Differences in Self-Reported Medication Nonadherence and its Drivers in Young Adults versus Older Adults with Systemic Lupus Erythematosus
Abstract Number: 2635

Differences in structural lesions of the spine between patients with early axSpA and non-axSpA chronic back pain: 2-year results of the SPACE Cohort
Abstract Number: 0358

Different Perspectives between Physicians and Patients on Treatment Priorities and Challenges in Still’s Disease
Abstract Number: 2246

Different Populations, Different SDAI Cut-Off? A Proposal for a New Remission Threshold in Brazilian RA Patients from a National Multicenter Study
Abstract Number: 0233

Differential Effects of GLP-1 Receptor Agonists versus SGLT2 Inhibitors on Hypoglycemia and Infection Risk in Diabetic Patients with Inflammatory Arthritis
Abstract Number: 1838

Differential Expression Of Activation Markers On dsDNA-reactive B-cells Between Healthy Subjects And SLE Patients Reveals Unconventional Extrafollicular Activation In SLE
Abstract Number: 2268

Differential Impact of Certolizumab Pegol, Etanercept, and Adalimumab on Rheumatoid Factor Reduction and Seroconversion in Rheumatoid Arthritis: A Propensity Score–Matched Study
Abstract Number: 1841

Differential metabolomic signatures along lupus nephritis spectrum
Abstract Number: 2403

Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].